Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.23 -0.1  -2.6%

Last Trade - 11:46am

Small Cap
Market Cap £167.6m
Enterprise Value £156.3m
Revenue £2.71m
Position in Universe 759th / 1830

BioPorto Announces Q3 2020 Report

Wed 18th November, 2020 7:58am
For best results when printing this announcement, please click on link below:

November 18, 2020
Announcement no. 21
Q3 2020 Report

BioPorto will this week initiate patient enrollment for trial of its COVID-19
rapid test

In April 2020, BioPorto deployed an accelerated process to develop an
accurate, rapid, point-of-care test for SARS-CoV-2, the virus that causes

The development process has progressed well in the past several months, and in
an important advancement, BioPorto will begin collection of patient samples at
the University of California, Davis this week. These samples are expected to
be collected and analyzed by the end of December. The data from this analysis
will form an essential part of the Company’s application for Emergency Use
Authorization (EUA), which BioPorto is planning to submit to the US Food and
Drug administration (FDA).

Provided the clinical study is completed according to plan and the EUA is
granted, BioPorto expects to be able to initiate commercialization in the
beginning of 2021.

Analytical studies for The NGAL Test™ application on track, but COVID-19
slows clinical enrollment

BioPorto announced the first patient enrollment for its US pediatric clinical
trial of The NGAL Test™ in June 2020. Since then, leading US children’s
hospitals have continued enrolling patients in the study, and BioPorto has
conducted analytical studies according to the Company’s plan. However, the
global second wave of SARS-CoV-2 infections has restricted BioPorto’s access
to hospitals and limited the health care system’s ability to process and
conduct studies according to the originally anticipated schedule. As a result,
BioPorto expects to finalize patient enrollment, complete the data analysis
and submit a De Novo application to the FDA in Q1 2021, based on the current
outlook for the COVID-19 pandemic.

Product sales of The NGAL Test grew by 58% year-to-date

In Q3 2020, revenue generated by sales of The NGAL Test was up 17% compared to
Q3 2019. After very strong performance of Research Use Only (RUO) sales in the
US in the first half of 2020, US sales in Q3 2020 grew by 2% versus the prior
year’s Q3, and were up 28% over Q2 2020. In Q3 sales in the Rest of the
World (ROW) increased by 80%.

In total, product sales of The NGAL Test in the first nine months of 2020
increased by 58% YoY to DKK 9.8 million, demonstrating that interest in NGAL
continues to expand worldwide.

CE Mark of NGALds for near-patient testing expected at the end of 2020

BioPorto expects to self-declare in the EU (CE Mark) its novel gRAD-based test
for near-patient measurement of NGAL by late-2020. BioPorto will immediately
thereafter initiate commercialization of the test in select countries through
established distribution channels.

BioPorto completes fully guaranteed Rights Issue with net proceeds of DKK 93.6

In September 2020, BioPorto initiated a fully guaranteed Rights Issue of
66,645,467 new shares with pre-emptive subscription rights for existing
shareholders. The fully guaranteed and highly oversubscribed Rights Issue was
successfully completed in October 2020 and yielded net proceeds of DKK 93.6
million. The cash will be allocated to finance the company’s operations
until October 2021 and to the further development of both NGAL products and
the gRAD platform, including the development of tests for new indications.

Guidance for 2020 maintained

BioPorto maintains its financial guidance for 2020, as most recently described
in the Interim Report for the second quarter of 2020. Revenue of approximately
DKK 30 million is expected in 2020. An operating loss (EBIT) of approximately
DKK 73 million is forecast for the year.


Peter M. Eriksen, CEO, Commented:

“I am happy with the operational execution of the organization in Q3 2020.
We maintained a solid momentum on sales of The NGAL Test – even compared to
a very strong Q3 last year – and saw growth in product driven sales of the
test of 58% year to date over the same period last year. This clearly shows
that revenue from the test has not been affected by COVID-19. In Q3 2020, we
also showed strong progress in the development of new rapid tests on the gRAD
platform. We are pushing hard to take the COVID-19 test to trials in Q4 2020
and anticipate generating revenue from this promising viral antigen test early
in 2021.

During the quarter, we started enrolling patients in a pediatric clinical
trial in the US for the De Novo application to the FDA for The NGAL Test. As
we are facing restricted access to hospitals due to the global second wave of
COVID-19, we have seen the pace of enrollment slow. This will delay the
enrollment completion to Q1 2021.

Finally, we initiated the largest fundraising campaign in BioPorto’s history
in Q3 2020 through a fully guaranteed Rights Issue. I am very satisfied with
the significant interest and support received from investors which resulted in
an oversubscribed issue that was completed in October 2020 with net proceeds
of DKK 93.6 million. This means we have capitalized BioPorto to enable us to
execute on an ambitious strategic trajectory with several critical milestones
ahead of us the next 12 months.”

Investor meeting

In connection with the release of the Interim Report for the nine months of
2020, BioPorto will host an online investor presentation on November 18, 2020
at 15:00 CET in Danish and at 16:00 CET in English. For further information
regarding the online investor meeting, please visit

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone +45 4529 0000, e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies
to clinicians and researchers around the world. We use our antibody and assay
expertise to transform novel research tools into clinically actionable
biomarkers that can make a difference in patients’ lives. BioPorto is
headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen
stock exchange  CPH:BIOPOR .

*     2020 11 18 Announcement no. 21
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.